📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Panacea Biotec Wins Major Tax Case; ₹329.49 Crore Tax Demand Cancelled by ITAT
Panacea Biotec has received a favorable ruling from the Income Tax Appellate Tribunal (ITAT) regarding long-standing tax disputes for Assessment Years 2005-06 to 2012-13. The ITAT dismissed eight appeals by the tax department and allowed two appeals by the company, effectively quashing the previous assessment orders. This decision results in the cancellation of a massive tax demand totaling ₹329.49 Crore. The ruling removes a significant contingent liability and potential penalty exposure from the company's financial records.
Key Highlights
ITAT quashed assessment orders for eight Assessment Years spanning 2005-06 to 2012-13.
Cancellation of a total tax demand amounting to ₹329.49 Crore previously raised by the Assessing Officer.
Deletion of all expense disallowances that were under litigation since Financial Year 2015-16.
The ruling dismisses eight appeals filed by the Deputy Commissioner of Income Tax (DCIT) against the company.
💼 Action for Investors
This is a significant positive development that strengthens the balance sheet by removing a large liability; investors should monitor if the tax department files a further appeal in the High Court.
Panacea Biotec Q3 Results: Consolidated Net Profit at ₹389 Lakh; Standalone Loss Widens
Panacea Biotec reported a consolidated net profit of ₹389 lakh for the quarter ended December 31, 2025, a slight decline from ₹444 lakh in the previous year. Consolidated revenue from operations grew marginally to ₹16,519 lakh compared to ₹16,349 lakh YoY. However, the standalone business faced significant pressure, reporting a net loss of ₹736 lakh against a profit of ₹965 lakh in the same period last year. The company continues to benefit from exceptional income, including a ₹858 lakh settlement with Apotex Inc. and deferred consideration from previous brand sales.
Key Highlights
Consolidated revenue from operations increased 1.04% YoY to ₹16,519 lakh.
Formulations segment EBIT turned positive at ₹906 lakh compared to a loss of ₹758 lakh in Q3 FY25.
Vaccines segment reported a loss of ₹257 lakh at the EBIT level for the quarter.
Exceptional income of ₹1,679 lakh recognized in 9M FY26, including ₹858 lakh from a settlement with Apotex Inc.
Standalone net loss for 9M FY26 widened significantly to ₹2,970 lakh from ₹284 lakh in 9M FY25.
💼 Action for Investors
Investors should exercise caution as the company remains loss-making on a 9-month consolidated basis despite the quarterly profit. Monitor the vaccines segment's recovery and the company's ability to generate consistent operational cash flow without relying on exceptional items.
Panacea Biotec Q3 FY26 Results: Consolidated Net Profit at ₹3.89 Cr; Revenue Grows 1% YoY
Panacea Biotec reported a consolidated net profit of ₹3.89 crore for Q3 FY26, a slight decline from ₹4.44 crore in the same quarter last year. Consolidated revenue from operations grew marginally by 1% YoY to ₹165.19 crore. For the nine-month period, the company remains in a net loss of ₹6.16 crore, though this narrowed from a loss of ₹6.73 crore in the previous year. The results were significantly supported by an exceptional income of ₹16.79 crore in the 9M period, including a settlement with Apotex Inc.
Key Highlights
Consolidated Q3 revenue reached ₹165.19 crore, a marginal 1% increase over the previous year's ₹163.49 crore.
Formulations segment profit improved significantly to ₹9.06 crore from a loss of ₹7.58 crore in Q3 FY25.
Vaccines segment reported a loss of ₹2.57 crore for the quarter despite revenue of ₹99.24 crore.
Exceptional income of ₹16.79 crore for 9M FY26 includes ₹8.58 crore from a settlement with Apotex Inc.
Standalone net loss stood at ₹7.36 crore for Q3 FY26, compared to a profit of ₹9.65 crore in Q3 FY25.
💼 Action for Investors
Investors should monitor the company's ability to sustain operational profitability without relying on exceptional items and brand sale deferrals. While the turnaround in the formulations segment is positive, the core vaccine business remains under pressure.
Panacea Biotec's Baddi Facility Receives GMP Non-Compliance From Hungary Regulator
Panacea Biotec's subsidiary facility in Baddi has received a 'Statement of non-compliance' with Good Manufacturing Practices (GMP) from Hungary's NCPHP, resulting in the revocation of its GMP certificates. The regulator has proposed halting supplies of non-vital products to the EU market, though no quality risks were found in products already released. The financial impact is expected to be minimal as the EU market contributed only 0.32% of the company's total consolidated net revenues in FY 2024-25. The company is currently implementing corrective and preventive actions (CAPA) to seek a re-inspection and restore compliance.
Key Highlights
NCPHP Hungary issued a Statement of non-compliance with GMP for the Baddi facility on February 03, 2026.
All valid GMP certificates issued by NCPHP for the facility have been revoked following the inspection.
Revenue from the European Union market accounted for only 0.32% of consolidated net revenues in FY 2024-25.
No quality risks were observed by regulators for products already released into the market.
Company is implementing CAPA and will request a re-inspection at the earliest to restore certificates.
💼 Action for Investors
Investors should note that while the immediate revenue impact is negligible at 0.32%, the regulatory failure at a major facility is a sentiment negative. Monitor the timeline for CAPA implementation and successful re-inspection to ensure no broader compliance issues exist.
Panacea Biotec Completes Phase III Enrollment for DengiAll Vaccine with 10,335 Participants
Panacea Biotec has achieved a major milestone by completing the enrollment of 10,335 participants for the Phase III clinical trials of DengiAll, India's first indigenous single-shot dengue vaccine. The trial, conducted in collaboration with ICMR, will now move into a two-year monitoring phase to evaluate the vaccine's efficacy and immunogenicity. This development keeps the company on track for a projected market entry by 2027. Successful commercialization would address a significant unmet medical need in tropical regions, potentially creating a substantial long-term revenue stream.
Key Highlights
Completed enrollment of 10,335 study participants for Phase III clinical trials of DengiAll vaccine.
DengiAll is positioned as India's first indigenous single-shot tetravalent dengue vaccine candidate.
Two-year monitoring period initiated to examine long-term efficacy and immunogenicity post-administration.
Commercial market launch is anticipated by 2027 following the completion of the observation period.
Project is being executed in collaboration with the Indian Council of Medical Research (ICMR).
💼 Action for Investors
Investors should maintain a positive outlook on the company's R&D pipeline as this milestone reduces execution risk. However, since commercialization is expected only by 2027, this remains a long-term play with interim clinical data being the next key catalyst.
Panacea Biotec Receives ₹9.38 Crore Income Tax Penalty Demand
Panacea Biotec Limited has received three demand orders from the Income Tax Department totaling ₹9.38 Crore. The penalties are attributed to alleged under-reporting of income for Assessment Years 2017-18, 2020-21, and 2021-22. The company has declared the demand as not maintainable and intends to file an appeal with the appellate authority. While the company does not foresee an immediate operational impact, the final resolution of this litigation will determine the actual financial outflow.
Key Highlights
Aggregate penalty demand of ₹9.38 Crore received from the Assistant Commissioner of Income Tax, Delhi.
Specific demands include ₹5.55 Crore for AY 2017-18, ₹3.11 Crore for AY 2020-21, and ₹0.72 Crore for AY 2021-22.
Penalties imposed under Section 270A of the Income Tax Act, 1961 for alleged under-reporting of income.
Company plans to contest the orders by filing an appeal with the relevant appellate authority.
💼 Action for Investors
Monitor the progress of the tax appeal as a negative outcome would result in a cash outflow of ₹9.38 Crore. No immediate action is required as the company is actively contesting the demand.
Panacea Biotec Secures ₹80 Crore Additional Vaccine Supply Orders from UNICEF
Panacea Biotec has received an amendment to its existing contract with UNICEF for the supply of its WHO pre-qualified Pentavalent vaccine, Easyfive-TT®. The total value of the award has been increased by approximately $8.93 million (around ₹80 Crore) for the years 2026 and 2027. Specifically, the 2026 allocation increased by $2.55 million, while the 2027 allocation saw a combined increase and additional award totaling $6.38 million. This development strengthens the company's long-term revenue visibility and reinforces its partnership with international health organizations.
Key Highlights
Total contract value increased by $8.93 million (~₹80 Crore) for CY2026 and CY2027
2026 supply value increased by $2.55 million to a total of $16.8 million
2027 supply value increased by $6.38 million through amendments and additional awards
Supplies involve the WHO pre-qualified fully liquid Pentavalent vaccine, Easyfive-TT®
The contract is with an international entity (UNICEF), ensuring high credit quality
💼 Action for Investors
This order provides strong revenue visibility for the next two years and validates the company's standing in the global vaccine market. Investors should monitor the impact on margins and the company's ability to scale production to meet these increased requirements.
Panacea Biotec: CFO Appointment, Company Secretary Change & Policy Revision
Panacea Biotec has announced key management changes. Mr. Vinod Goel, currently Group CFO, is appointed as CFO effective December 16, 2025, succeeding Mr. Devender Gupta. Consequently, Mr. Goel will cease to be the Company Secretary. Mr. Ankit Jain is appointed as Company Secretary and Compliance Officer from December 16, 2025. The board also adopted a revised policy for determining the Materiality of Events.
Key Highlights
Mr. Vinod Goel appointed as Group Chief Financial Officer and Head Legal & Corporate Governance w.e.f. December 16, 2025.
Mr. Ankit Jain appointed as General Manager – Legal & Company Secretary w.e.f. December 16, 2025.
Mr. Vinod Goel has over 35 years of post-qualification experience.
Mr. Ankit Jain has around 15 years of experience in corporate governance and regulatory compliance.
Revised Policy for determining Materiality of Events / Information effective December 16, 2025.
💼 Action for Investors
Investors should note the changes in key management personnel. Monitor future filings for any impact from the revised policy on materiality of events.